Advances in Research and Application of Liquid Biopsy in Lymphoma

Yang Zhang, Yu Zhang, Hongxing Liu


Liquid biopsy as a new rising non-invasive testing method plays an important role in assist of the diagnosis, evaluation of the efficacy and prognosis, monitoring of early recurrence and drug resistance. It has been widely applied in some type of solid tumors. Lymphoma is a group of heterogeneous hematological malignancies which most subtypes without specific tumor markers and evaluation of the efficacy and prognostic is mainly depends on and limited to biopsy and imaging. Compared to other solid tumors, lymphoma tumor cells were characterized with access to peripheral easier and immunoglobulin molecules diversity can be monitored as marker, which is more applicable to liquid biopsy. With advances in the detection technology, research and application of liquid biopsy in lymphoma has attracted more attentions.


Liquid Biopsy, Circulating Tumor DNA, Lymphoma

Full Text:



Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. J Mol Diagn. 2015;17(3):209-224. doi:10.1016/j.jmoldx.2015.02.001.

Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 2016;164(1-2):57-68. doi:10.1016/j.cell.2015.11.050.

Aarthy R, Mani S, Velusami S, Sundarsingh S, Rajkumar T. Role of circulating cell-free DNA in cancers. Mol Diagn Ther. 2015;19(6):339-350. doi:10.1007/s40291-015-0167-y.

Tickner JA, Urquhart AJ, Stephenson SA, Richard DJ, O’Byrne KJ. Functions and therapeutic roles of exosomes in cancer. Front Oncol. 2014;4:127. doi:10.3389/fonc.2014.00127.

Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646-650.

Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10(20):6897-6904. doi:10.1158/1078-0432.CCR-04-0378.

Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra224. doi:10.1126/scitranslmed.3007094.

Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199-1209. doi:10.1056/NEJMoa1213261.

Hohaus S, Giachelia M, Massini G, et al. Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Oncol. 2009;20(8):1408-1413. doi:10.1093/annonc/mdp006.

Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16(5):541-549. doi:10.1016/S1470-2045(15)70106-3.

Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548-554. doi:10.1038/nm.3519.

Scherer F, Kurtz DM, Newman AM, et al. Noninvasive genotyping and assessment of treatment response in diffuse large B cell lymphoma. Blood. 2015;126(23):114.

Rasi S, Monti S, Zanni M, et al. Liquid biopsy as a tool for monitoring the genotype of diffuse large B-cell lymphoma. Blood. 2015;126(23):127.

Fontanilles M, Marguet F, Bohers É, et al. Somatic mutations detected in plasma cell-free DNA by targeted sequencing: assessment of liquid biopsy in primary central nervous system lymphoma. Blood. 2015;126(23):332.

Nakamoto-Matsubara R, Sakata-Yanagimoto M, Nguyen T, et al. G17V Rhoa mutation in circulating DNA is a useful marker for diagnosis of AITL and AITL-related lymphoma. Blood. 2015;126(23):1447.

Frickhofen N, Muller E, Sandherr M, et al. Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with B-cell neoplasia. Blood. 1997;90(12):4953-4960.

Armand P, Oki Y, Neuberg DS, et al. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013;163(1):123-126. doi:10.1111/bjh.12439.

Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125(24):3679-3687. doi:10.1182/blood-2015-03-635169.

Kurtz DM, Scherer F, Newman AM, et al. Dynamic noninvasive genomic monitoring for outcome prediction in diffuse large B-cell lymphoma. Blood. 2015;126(23):130.

Roschewski M, Dunleavy K, Pittaluga S, et al. Monitoring of circulating tumor DNA as minimal residual disease in diffuse large B-cell lymphoma. Blood. 2014;124(21):139.

Sarkozy C, Huet S, Carlton V, et al. Quantitative assessment of circulating clonal IG-VDJ sequences in plasma of follicular lymphoma at diagnosis is highly predictive of progression free survival (PFS). Blood. 2015;126(23):2675.

Mussolin L, Burnelli R, Pillon M, et al. Plasma cell-free DNA in paediatric lymphomas. J Cancer. 2013;4(4):323-329. doi:10.7150/jca.6226.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Creative Commons License
International Journal of Medical Reviews is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.